Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer; Ovarian Cancer; Gynecologic Cancers; Ovarian/Peritoneal/Fallopian Cancer

Detailed Description

1. To establish a demographic database to evaluate the efficacy of medical interventions in patients and relatives who carry BRCA1 and 2 mutations and to compare these outcomes to patients who do not carry a BRCA1 or 2 mutation.
2. To obtain blood samples from patients who undergo genetic testing to a) evaluate the incidence of genetic modifier polymorphisms involved in the development of cancer in BRCA1 and 2 mutation carriers and to compare this incidence to non-BRCA 1 and 2 carriers. b) to understand the interaction of genetic modifiers and BRCA1 and 2 in the development of cancer. c) to determine the effect of environmental influences on the incidence of polymorphisms in genetic modifiers and on the penetrance of BRCA1 and 2 mutations by linking information from our demographic database to blood samples and
3. To obtain tumor tissue from BRCA1 and 2 carriers to utilize for gene expression studies.
4. To establish a cohort of sporadic breast cancer patients, or women with no family history of cancer in a first degree relative, to serve as a comparison group to women with strong family history of breast cancer.
5. To establish a cohort of healthy volunteers without personal or family history of cancer to serve as a comparison group to women with sporadic and familial breast cancer.

• Study Type: Observational
• Enrollment (Estimated): 3300

Contacts and Locations

• Study Contact: Name: Meredith Mills; Phone Number: (650) 724-5223; Email: bluett@stanford.edu

Study Locations

• United States
  • California
    • Stanford, California, United States, 94305
      • Recruiting
      • Stanford University School of Medicine
      • Sub-Investigator: Allison Walsh Kurian
      • Contact: Meredith Mills; Phone Number: 650-724-5223; Email: bluett@stanford.edu
      • Principal Investigator: James M Ford

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Women who have a high risk of developing breast or ovarian cancer due to a known germline mutation in the BRCA1/2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong family history of either breast or ovarian cancer, in the absence of known cancer susceptibility gene mutation.

Description

Inclusion Criteria:

I. Women who have a high risk of developing breast or ovarian cancer due to a known germline mutation in the BRCA1/2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong family history of either breast or ovarian cancer, in the absence of known cancer susceptibility gene mutation.

II. Women who are approaching surgery for resection of a pelvic mass, which is considered suspicious for neoplasia by radiologic or clinical criteria; such women may or may not also meet criteria for inclusion in group I.

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Stanford University
• Collaborators: Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation
• Investigators: Principal Investigator: James M Ford, Stanford University

Study record dates

Study Major Dates

• Study Start: August 1, 2001
• Primary Completion (Estimated): January 1, 2099
• Study Completion (Estimated): January 1, 2099

Study Registration Dates

• First Submitted: December 16, 2009
• First Submitted That Met QC Criteria: December 16, 2009
• First Posted (Estimated): December 17, 2009

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 5, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: quality of life
• Other Study ID Numbers: IRB-11872; SU-11022007-786 (Other Identifier: Stanford University); BRSNSTU0020 (Other Identifier: OnCore)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No